PTO/SE/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons a	are required to respond to a collection of	information unless it contains a valid OMB control number.
Substitute for form 1449A-B/PTO	C	omplete if Known
,	Application Number	10/672,302
INFORMATION DISCLOCATE STATEMENT BY APPLICANT	Filing Date	September 26, 2003
STATEMENT BY APP(ICANT	First Named Inventor	Hong Jin
STATEMENT BY APPLICANT	Group Art Unit	1648
F PPA B = 4934	Examiner Name	Unassigned
(use as many sheets as hecessary)	Attorney Docket Number	26-000320US
	Date Submitted	January 27, 2004

	_	\ \	A 44/		,,,	-
		Many	200			
				S. PATENT DOCUMENTS		
		U.S. Patent Document		Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
ВВ	01	5,922,326		Murphy et al.	07-13-1999	
						•
				·		
					1	1

	FOREIGN PATENT DOCUMENTS								
			Foreign Patent Docu			Date of Publication	Pages, Columns, Lines,	Γ	
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T	
BB	02	wo	02/44334	A2	Aviron, Inc.	06-06-2002			

			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
	Examiner Cite Initials No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т	
BB 03		ORF of the M2 gene of pneumoviruses. J Gen Virol., 80:2011-2016.			
O4 Ahmadian et al. (2000) Expression of the ORF-2 protein of the human res M2 gene is initiated by a ribosomal termination-dependent reinitiation mech 19:2681-2689.		Ahmadian et al. (2000) Expression of the ORF-2 protein of the human respiratory syncytial M2 gene is initiated by a ribosomal termination-dependent reinitiation mechanism. EMBO J., 19:2681-2689.			
	05 06 07		Anderson et al. (1985) Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J Clin Microbiol., 22:1050-1052.		
			Asenjo et al. (2000) Regulated but not constitutive human respiratory syncytial virus (HRSV) P protein phosphorylation is essential for oligomerization. FEBS Lett 467:279-284		
			07		07
reg		08	Bermingham et al. (1999) The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A, 96:11259-11264.		
BI	В	09	Bukreyev et al. (1996) Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol, 70:6634-6641.		

Signature /Benjamin Blumel/ Considered 11/30/2006	Examiner Signature	/Benjamin Blumel/	Date Considered	11/30/2006
---	-----------------------	-------------------	--------------------	------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is In conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTC/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Under the Pag Substitute for

(use as many sheets as necessary)

C	omplete if Known				
Application Number 10/672,302					
Filing Date	September 26, 2003				
First Named Inventor	Hong Jin				
Group Art Unit	1648				
Examiner Name	Unassigned				
Attorney Docket Number	26-000320US				
Date Submitted	January 27, 2004				

BB	10	BB respiratory syncytial virus to the P protein gene. J. Gen Virol. 73:865-873						
	11 Cheng et al. (2001) Chimeric Subgroup A Respiratory Syncytial Virus with the Glycoproteins Substituted by Those of Subgroup B and RSV without the M2-2 Gene are Attenuated in African Green Monkeys. Virology 283:59-68							
	12	Cheng et al. (2002) Expression of ß-galactosidase by recombinant respiratory syncytial viruses for microneutralization assay. J Virol Methods 105:287-96						
13 Collins et al. (1985) The envelope-associated 22K protein of human respirator virus: nucleotide sequence of the mRNA and a related polytranscript. J Virol, 54								
	Collins et al. (1995) Production of infectious human respiratory syncytial virus from cloned cDNA confirms and essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. 92:11563-11567							
	Dupuy et al. (1999) Casein Kinase 2-Mediated Phosphorylation of Respiratory Synctial Virus Phosphoprotein P is Essential for the Transcription Elongation Activity of the Viral Polymerase; Phosphorylation by Casein Kinase 1 Occurs Mainly at Ser <sup>215</sup> and is without Effect. J. Virol. 73:8384-8392							
	16 Faulkner et al. (1976) Respiratory Syncytial Virus ts Mutants and Nuclear Immunofluorescence. J. Virol. 20:487-500							
	17	Garcia-Barreno et al. (1996) Identification of Pro Human Respiratory Syncytial Virus Phosphoprot Nucleocapsid Assembly and Formation of Cytop	ein and Nucleoprtein:	Significance for				
	18	Hardy et al. (1998) The product of the respirator readthrough of intergenic junctions during viral tr						
	19	Hardy et al. (1999) Diverse Gene Functions of F Efficiency of Transcription Termination and Resp Antitermination. J Virol. 73: 170-176.						
	20	Hardy et al. (2000) The Cys <sub>3</sub> -His <sub>1</sub> Motif of the ReEssential for Protein Function. J. Virol. 74: 5880-		rus M2-1 Protein is				
	21	Jin et al. (1998) Recombinant Human Respiratory Syncytial Virus (RSV) from cDNA and Construction Subgroup A and B Chimeric RSV. Virology 251:206-214						
	22	Jin et al. (2000) Recombinant Respiratory Syncytial Viruses with Deletions in the NS1, NS2, SH, and M2-2 Genes are Attenuated <i>in Vitro</i> and <i>in Vivo</i> . Virology 273:210-218						
BB	23							
Examine Signatu		/Benjamin Blumel/	Date Considered	11/30/2006				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Under the Pap

Substitute for fox 3449A-B/PT INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

C	omplete if Known
Application Number	10/672,302
Filing Date	September 26, 2003
First Named Inventor	Hong Jin
Group Art Unit	1648
Examiner Name	Unassigned
Attorney Docket Number	26-000320US
Date Submitted	January 27, 2004

BB	24	Jin et al. (2003) Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21:3647-3652
25		Khattar et al. (2001) Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P and P-L interactions using a minigenome system. J. Gen Virol. 82:775-779
	26	Lu et al. (2002) Identification of Temperature-Senstive Mutations in the Phosphoprotein of Respiratory Syncytial Virus that are Likely Involved in its Interaction with the Nucleoprotein. J. Virol. 76:2871-2880
	27	Lu et al. (2002) The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro. J Virol. 76:10776-10784.
	28	Mallipeddi et al. (1996) Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P interaction using a two-hybrid system. J. Gen Virol. 77:1019-1023
	29	Marriott et al. (1999) A single Amino Acid Substitution in the Phosphoprotein of Respiratory Syncytial Virus Confers Thermosensivity in a Reconstituted RNA Polymerase System. J. Virol. 73:5162-5165
	30	Slack et al. (1998) Characterization of the interaction of the human respiratory syncytial virus phosphoprotein and nucleocapsid protein using the two-hybrid system. Virus Research 55:167-176
	31	Tang et al. (2001) Requirement of Cysteines and Length of the Human Respiratory Syncytial Virus M2-1 Protein for Protein Function and Virus Viability. J. Virol. 75:11328-11335
	32	<b>Techaarpornkul</b> et al. (2001) Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol, 75:6825-6834.
	33	Teng et al. (2000) Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol, 74:9317-9321.
	34	Whitehead et al. (1998) A Single Nucleotide Substitution in the Transcription Start Signal of the M2 Gene of Respiratory Syncytial Virus Vaccine Candidate cpts248/404 is the Major Determinant of the Temperature-Senstitive and Attenuation Phenogypes. Virology 247:232-239
ВВ	35	Zhou et al. (2003) Identification of amino acids that are critical to the processivity function of respiratory syncytial virus M2-1 protein. J Virol, 77:5046-5053.

Examiner	/Danienie Dlamal/	Date	11/20/2006
Signature	/Benjamin Blumel/	Considered	11/30/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A-B/PTO	C	Complete if Known		
	Application Number	10/672,302		
P E INFORMATION DISCLOSURE	Filing Date	September 26, 2003		
O \   SATEMENT BY APPLICANT	First Named Inventor	Hong Jin		
2004 12	Group Art Unit	1648		
APR 1 5 2004	Examiner Name	Unassigned		
(use as many sneets as necessary)	Attorney Docket Number	26-000320US		
	Date Submitted	April 13, 2004		

	U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	U.S. Patent Di Number	ocument Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal			
BB	01	6,713,066	B1	Collins et al.	03-30-2004				
7.									
	ļ -				<u> </u>				

Examiner Initials	Cite No.	Foreign Patent Document			N PATENT DOCUMEN	Date of Publication	Pages, Columns, Lines,	Т
		Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Ľ
								L
,				•				Γ
						· · · · · · · · · · · · · · · · · · ·		Γ
			<u> </u>					T
	•							H
								┡

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т				
			igapha				
		·					

Examiner		Date	
1	/- ' /	Date	11/20/2006
Signature	Benjamin Blumel/	Considered	11/30/2006
Cignatule	7 - 5 - 3	Considered	' '

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.